Prospective validation of the Cancer and Aging Research Group fall-risk score for older adults with cancer.
Abstract
e23195 Background: In older adults with cancer, falls are associated with poorer quality of life, chemotherapy toxicity & shorter survival, yet fall risk factors in this population are unclear. In a prior cross-sectional study, we developed & validated a model of factors associated with falls in older adults on systemic therapy. In this study, we aimed to prospectively validate the Cancer & Aging Research Group fall-risk score (CARG FRS) & explore whether additional variables or time-varying covariates improved the model’s performance. Methods: This prospective cohort study enrolled participants aged ≥70 years with cancer, receiving systemic cancer therapy & life expectancy > 1 year. Baseline assessment comprised measures of functional status, prior falls, medications, cognition, physical function, depression, neuropathy, and pain. The primary outcome was falls, prospectively ascertained over 6-months follow-up. Descriptive statistics were calculated on all study variables and risk model scores were computed. Non-parametric correlations assessed the relationship between baseline CARG FRS and falls during the study. Receiver operating characteristic (ROC) analyses determined area under the curve (AUC) values. A linear mixed model (LMM) examined if CARG scores changed over time. Extended Cox proportional hazards models examined prediction of falls based on a time-varying fall-risk score. IBM SPSS version 28 was used for all analyses; a .05 alpha level determined statistical significance. Results: 213 participants had a mean age 72.2 yrs ±SD = 5.5; 55% were male, 90% white. One-quarter (54/213, 25.4%) had ≥1 fall during follow-up. The average baseline CARG FRS was 5.7 ± 3.5, range 0-16. The baseline fall-risk score as previously published had a small, but not significant, relationship with falls (r = .131, p = .057); modifications of the previously published cutpoints for polypharmacy and depression scores based on the distribution in our cohort improved prediction of falls using baseline CARG scores (r = .163, p = .017). However, neither the original CARG FRS or the modified scores provided good discrimination among fallers and non-fallers (area under the curve .586 and .608, respectively). While individuals with prior falls were significantly more likely to fall during follow-up than those without prior falls (41% vs 18%, p < .001), stratifying by prior falls did not result in significance of the FRS for either group. The CARG FRS as a time-varying predictor did not have a statistically significant relationship with falls. Conclusions: In this external validation of the CARG FRS, the modified model was statistically significant in predicting falls over 6-months of follow-up, but with poor discrimination. Stratifying by prior falls or adding time-varying predictors did not yield an improved risk prediction model. Future research is needed to create accurate risk-prediction models for clinical use.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (6)
Tanya Marya Wildes
University of Nebraska Medical Center, Omaha, NE
Kevin Kupzuk
Home, Omaha, NE
Laura LaNiel Tenner
University of Nebraska Medical Center, Omaha, NE
Thuy Koll
2University of Nebraska Medical Center, Omaha, United States
Kristin Dickinson
University of Pittsburgh, Pittsburgh, PA
Katherine Clifton
Washington University School of Medicine, St. Louis, MO